2-Methyl-3-(β-amino-propyl)-indol | 4966-28-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-Methyl-3-(β-amino-propyl)-indol
• 英文别名: 3-(2-Amino-propyl)-2-methyl-indol；1-methyl-2-(2-methyl-indol-3-yl)-ethylamine；1H-Indole-3-ethanamine, alpha,2-dimethyl-；1-(2-methyl-1H-indol-3-yl)propan-2-amine
• CAS: 4966-28-3
• 化学式: C₁₂H₁₆N₂
• mdl: MFCD08453448
• 分子量: 188.272
• InChiKey: AXZQFXRPULJFQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  41.8
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs
  申请人：Codexis, Inc.

  公开号：US10544402B2

  公开（公告）日：2020-01-28

  The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents.

  本公开提供了用于生产胺的工程化转氨酶多肽、编码工程化转氨酶的多核苷酸、能够表达工程化转氨酶的宿主细胞，以及使用工程化转氨酶制备用于生产活性药剂的化合物的方法。
• Psilocybin compositions
  申请人：Stamets Paul Edward

  公开号：US11471450B2

  公开（公告）日：2022-10-18

  Methods and compositions are disclosed for enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning using fungal extracts and their active ingredients, including species of mushrooms and mycelia containing psilocybin and psilocin, combined with erinacines and hericenones or fungal extracts containing those active ingredients, with the addition of nicotinic acid. The compositions may optionally be combined with nervine plants.

  本发明公开了使用真菌提取物及其有效成分（包括含有茜草素和茜草素的蘑菇种类和菌丝体），结合麦角苷和茜草素或含有这些有效成分的真菌提取物，并添加烟酸，来增强神经发生、解决神经病变和改善神经系统健康和功能的方法和组合物。组合物还可选择与神经性植物结合使用。
• BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS
  申请人：Codexis, Inc.

  公开号：EP2828385B1

  公开（公告）日：2018-02-07
• COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID
  申请人：CaaMTech, LLC

  公开号：US20190142851A1

  公开（公告）日：2019-05-16

  This disclosure pertains to new compositions and methods comprising a psilocybin derivative. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, or purified terpene.
• COMPOSITIONS OF PSILOCYBIN AND ANALOGS
  申请人：STAMETS Paul Edward

  公开号：US20200375967A1

  公开（公告）日：2020-12-03

  Methods and compositions are disclosed for enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning using fungal extracts and their active ingredients, including species of mushrooms and mycelia containing psilocybin and psilocin, combined with erinacines and hericenones or fungal extracts containing those active ingredients, with the addition of nicotinic acid. The compositions may optionally be combined with nervine plants.